AMENDMENTS TO THE CLAIMS

Please amend claims 1-6 as follows:

- 1. (Currently Amended) An agent for treatment of pemphigoid, containing comprising interferon-γ as an active ingredient.
- 2. (Currently Amended) The agent for treatment according to claim 1, which is administered in a form suitable for administration in a daily dose of 200,000 to 4,000,000 JRU, preferably 2,000,000 JRU.
- 3. (Currently Amended) The agent for treatment according to claim 1-or 2, which is <u>in a</u> form suitable-pharmaceutical preparation for intravenous injection.
- 4. (Currently Amended) The agent for treatment according to <u>claim 1</u>, <u>further comprising</u> any one of claims 1 to 3, which is used in combination with an antihistaminic, an antiallergic and/or a corticosteroid.
- 5. (Currently Amended) The agent for treatment according to any one of claims 1-to 4, wherein pemphigoid is bullous pemphigoid, cicatricial pemphigoid, or nodular pemphigoid.
- 6. (Currently Amended) The agent for treatment according to any one of claims 1-to 4, wherein pemphigoid is bullous pemphigoid.
- 7. (New) The agent for treatment according to claim 2, wherein said daily dose is, 2,000,000 JRU.
- 8. (New) The agent for treatment according to claim 1, wherein said interferon-γ is an interferon-γ mutant.
- 9. (New) A therapeutic composition comprising interferon-γ as an active ingredient and a pharmaceutically acceptable carrier, said interferon-γ being present in an amount effective to treat pemphigoid.

- 10. (New) A method for treating pemphigoid comprising administering to a patient the therapeutic composition of claim 9.
- 11. (New) The method according to claim 10 comprising administering said composition intravenously.